Hyaluronidase/Rituximab

透明质酸酶/利妥昔单抗

Report date: 2023/05/05 17:34:40

Base Information

Drug NameHyaluronidase/Rituximab
Drug Alias NameRituxan Hycela
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsHyaluronic acid modulators +[5] 
TargetsHyaluronic acidB-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLeukemia, Lymphocytic, Chronic, B-Cell
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2017/06/22
Country/TerritoryUnited States
CombinationsYes Hyaluronidase recombinant humanRituximab
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesGenentech Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeL01XC
Related LinksN/A